Cigna Incentive Program Offers $500 to Switch from Biologics to Biosimilars, Drug Savings Could Reach $375 Billion

In an effort to promote biosimilars, Cigna is offering $500 if customers switch to a lower-cost offering. Experts project that the move to biosimilars could bring enormous savings—between $225 and $375 billion. Cigna is especially interested in reducing costs for drugs used in inflammatory diseases. These drugs are typically expensive and pose a significant financial burden to patients.

Cigna’s Chief Clinical Officer Dr. Steve Miller notes, “Biosimilars can save patients, their employers, health plans and the health care system billions of dollars over the long term. We believe that patients should be the first to benefit, which is why we’re sharing these savings with them up front.” Read more here.

(Source: Christine Blank, Managed Healthcare Executive, 7/6/21)